Civica, Inc.

• California's ambitious $100-million CalRx insulin initiative, announced two years ago with a promised 2024 delivery, is significantly behind schedule with potential delays extending to 2030. • Civica, Inc., the contracted manufacturer, has not yet begun clinical trials or FDA approval process for the five planned insulin types, though manufacturing has commenced. • The delay impacts over 3.5 million Californians with diabetes, while alternative solutions like insulin price caps have been vetoed by Governor Newsom in favor of the CalRx program.